Physician profile
Daniel John Vandenberg
NPI 1699865568
$2,144.44
in general payments reported to CMS, 2019-2025
16 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.44 · 2022: $300 · 2023: $383 · 2024: $1,118 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181 · Travel and Lodging: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.35 |
| Travel and Lodging | $649.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $916.85 | 2022-2025 | Mounjaro, Zepbound |
| Stryker Corporation | $649.92 | 2024 | Mako |
| Novartis Pharmaceuticals Corporation | $117.15 | 2022-2023 | |
| Exact Sciences Corporation | $87.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $76.18 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.52 | 2022-2024 | Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $48.44 | 2023 | Bexsero, Menveo, Pediarix |
| Abbvie INC. | $40.75 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.30 | 2024 | |
| Novo Nordisk INC | $20.14 | 2025 | |
| Sumitomo Pharma America, INC. | $16.98 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $15.78 | 2025 | Zoryve |
| Amgen INC. | $15.67 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $15.61 | 2024 | Delstrigo, Pifeltro, Dificid |
| Cranial Technologies, INC | $13.85 | 2023 | Doc Band |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vandenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.